FibroBiologics (Nasdaq: FBLG) has received full regulatory approval in Australia to initiate a 120-patient Phase 1/2 trial of CYWC628, its fibroblast-based cell therapy for refractory diabetic foot ulcers—a market with urgent unmet need. The trial, managed by CRO partner Southern Star Research, marks a major step toward commercializing a novel regenerative treatment in the multibillion-dollar chronic wound care space.

XTI Aerospace (Nasdaq: XTIA) reported a pivotal Q3 marked by successful subscale test flights for its TriFan 600 VTOL aircraft, continued FAA certification engagement, and the selection of Garmin’s G700 TXi avionics suite. The company bolstered its balance sheet with $18.5M in fresh capital and expanded its footprint in unmanned aviation through the acquisition of Drone Nerds and a $25M strategic investment from Unusual Machines, setting the stage for long-term leadership in the fast-emerging Vertical Economy.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) has launched patient enrollment at Mount Sinai for its groundbreaking B-FREE Phase 2 study—the first to evaluate a treatment for chronic babesiosis, a debilitating tick-borne illness with no FDA-approved therapy. Targeting up to 100 patients, the 90-day tafenoquine trial aims to address severe fatigue and establish diagnostic benchmarks in a market estimated between 4,400 and 190,000 U.S. cases annually.

FatPipe (Nasdaq FATN) CEO Dr. Ragula Bhaskar issued a shareholder letter addressing recent stock volatility tied to IPO lockup expiration, emphasizing strong fundamentals and continued momentum in the SD-WAN and cybersecurity sectors. With current revenue multiples significantly below industry peers, the company sees a compelling value opportunity as it scales recurring revenue and expands its presence across enterprise and public sector markets.